The 2022 SOHO ASTX727 combined with venetoclax is expected to improve the prognosis of patients with relapsed or treatment-naïve AML

The inclusion criteria were: (1) ≥ 18-year-old patients with R/R AML; (2) ≥ 75 years old or 18-74 years old with prohibited intensive chemotherapy (first-line therapy; FL) patients with AML with comorbidities; (3) Good
organ function.
Repeat a cycle every 4-8 weeks, with patients taking ASTX727 orally on days 1-5 of each cycle, ven orally on days 1-28 of cycle 1 (after dose increase of 100-200-400 mg over 3 days), and ven orally on days 1-21 in subsequent
cycles.
Patients have a bone marrow examination on days 21±3 and if the blasts are <5%, VEN is suspended to allow the cell count to recover
.
Depending on the recovery of the patient's cell count, the dose and duration
of both drugs can be reduced.
Growth factors can be used to promote cell count recovery
.

A total of 37 patients (FL cohort: 28 and R/R cohort: 9)
were included.
The median age of patients was 75 years (range: 46-92).

The overall response rate (ORR) in the FL cohort was 57% (7 patients complete response [CR], 8 patients CR with incomplete recovery of blood count [CRi], 1 patient morphologically free of leukemia status [MLFS], 10 patients non-responding, 2 patients could not be assessed), and the ORR in the R/R cohort was 56% (3 patients CR, 1 patient CRi, 1 patient MLFS, 4 patients did not respond
).
The characteristics and efficacy of patients are shown
in Table 1.

Table 1

At a median follow-up of 7 months, median overall survival (OS) was not achieved in the FL cohort (range: 0.
6-13) and median OS in the R/R cohort was 10.
1 months (range: 3.
2-13).

The survival of the patient is shown
in Figure 1.

Figure 1

Grade ≥ 3 adverse events were mainly associated with
myelosuppression.
Four patients (11%) developed neutrophil infection and one patient (3%) developed elevated
liver enzymes.